Articles related to AGE-RELATED MACULAR DEGENERATION (AMD)
Thioridazine Retinal Toxicity
When atypical AMD is suspected, additional multimodal imaging and a more detailed medical history are required to establish the correct diagnosis. The medical history, clinical examination, and retinal imaging findings of a 69-year-old White man with a long-standing medical history of schizophrenia, bilateral visual decline, nyctalopia, and blurred vision were sufficient evidence for the doctors to establish a presumed diagnosis of thioridazine retinal toxicity. Although it is a rare diagnosis due to the introduction of newer medications, patients with an underlying psychiatric history and atypical retinal findings on examination may have been or are currently taking the culprit psychotropic medication.
Ophthalmology March 28th 2023
FDA Approves Apellis’ Syfovre (Pegcetacoplan), First and Only Treatment for Geographic Atrophy
The every-other-month intra-ocular injection shows a reduction in lesion growth that increases over time. The ocular formulation of the drug, previously approved for paroxysmal nocturnal hemoglobinuria, should be available in specialty pharmacies in March 2023.
Clinical Pharmacology February 28th 2023
Study: Form of AMD Strongly Associated with Cardiovascular Disease
Researchers used retinal imaging to examine the eyes of 200 people with age-related macular degeneration (AMD) to see who had subretinal drusenoid deposits (SDDs). Patients were asked to fill out a questionnaire about their family history of cardiovascular disease. There were 97 SDDs and 103 drusen only among the 200 patients. 47 of the 200 patients had severe heart disease, and 40 of the 47 (86%) had SDDs. In comparison, 57 (43%) of the 153 AMD patients who did not have these severe diseases had SDDs. According to the researchers, AMD patients who had these severe cardiovascular diseases and strokes were nine times more likely to have SDDs than those who did not.
Ophthalmology December 12th 2022